Non-suppressible viraemia during HIV-1 therapy: a challenge for clinicians
A Esteban-Cantos, R Montejano, A Pinto-Martínez… - The Lancet …, 2024 - thelancet.com
In individuals receiving antiretroviral therapy (ART), persistent low-level viraemia not
attributed to suboptimal ART adherence, detrimental pharmacological interactions, or drug …
attributed to suboptimal ART adherence, detrimental pharmacological interactions, or drug …
[HTML][HTML] Dynamics of Low-Level Viremia and Immune Activation after Switching to a Darunavir-Based Regimen
AJ Stam, NVEJ Buchholtz, WFW Bierman, R van Crevel… - Viruses, 2024 - mdpi.com
There is an ongoing debate regarding whether low-level viremia (LLV), in particular
persistent LLV, during HIV treatment with optimal adherence originates from low-level viral …
persistent LLV, during HIV treatment with optimal adherence originates from low-level viral …
[HTML][HTML] Predicting factors of plasma HIV RNA undetectability after switching to co-formulated bictegravir, emtricitabine, and tenofovir alafenamide in experienced HIV …
M Basso, G Battagin, S Nicolè, MC Rossi, F Colombo… - Viruses, 2023 - mdpi.com
Switching to bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF) from other
antiretroviral regimens is safe and effective for virologically suppressed people living with …
antiretroviral regimens is safe and effective for virologically suppressed people living with …
Clinical significance and management of low‐level HIV viremia in the era of integrase strand transfer inhibitors
J Shi, G Ying, R Zheng, Z Zhang - HIV medicine, 2024 - Wiley Online Library
Background People living with HIV (PLWH) and receiving antiretroviral therapy (ART) have
a goal of achieving and maintaining viral suppression; however, the existence of PLWH that …
a goal of achieving and maintaining viral suppression; however, the existence of PLWH that …
Tenofovir-Diphosphate and Emtricitabine-Triphosphate Adherence Benchmarks in Dried Blood Spots for Persons With Human Immunodeficiency Virus Receiving …
RP Coyle, M Morrow, SC Mann… - Clinical Infectious …, 2024 - academic.oup.com
Background QUANTI-TAF aimed to establish tenofovir-diphosphate/emtricitabine-
triphosphate (TFV-DP/FTC-TP) adherence benchmarks in dried blood spots (DBS) for …
triphosphate (TFV-DP/FTC-TP) adherence benchmarks in dried blood spots (DBS) for …
[HTML][HTML] The virological consequences of low-level viraemia
BO Olakunde, EE Ezeanolue - The Lancet Global Health, 2022 - thelancet.com
With highly active antiretroviral therapy (ART), people living with HIV can achieve and
maintain viral suppression below a detectable level, preventing transmission of HIV and …
maintain viral suppression below a detectable level, preventing transmission of HIV and …
[HTML][HTML] Incidence of low-level viremia and its impact on virologic failure among people living with HIV who started an integrase strand transfer inhibitors: a longitudinal …
X Lao, H Zhang, M Deng, Q Li, Q Xiao, L He… - BMC Infectious …, 2024 - Springer
Background Low-level viremia (LLV) has been identified as a potential precursor to virologic
failure (VF), yet its clinical implications, particularly within the context of Integrase Strand …
failure (VF), yet its clinical implications, particularly within the context of Integrase Strand …
Prevalence and predictors of persistent low-level HIV viraemia: a retrospective cohort study among people receiving dolutegravir-based antiretroviral therapy in …
Background: Persistent low-level viraemia (PLLV) is a risk factor for virologic failure among
people receiving antiretroviral therapy (ART). Objectives: We assessed the prevalence and …
people receiving antiretroviral therapy (ART). Objectives: We assessed the prevalence and …
Effectiveness of intensive adherence counselling in achieving an undetectable viral load among people on antiretroviral therapy with low‐level viraemia in Uganda
N Nanyeenya, D Nakanjako, F Makumbi… - HIV …, 2024 - Wiley Online Library
Introduction Uganda was using a threshold of 1000 copies/mL to determine viral non‐
suppression for antiretroviral therapy monitoring among people living with HIV, prior to this …
suppression for antiretroviral therapy monitoring among people living with HIV, prior to this …
[PDF][PDF] Predictors of Low-Level Viremia in People Living with HIV with Unsuppressed Viremia, A Retrospective Follow-up Study in Izmir
İ Akbulut, S Atalay - HAYDARPAŞA NUMUNE MEDICAL … - jag.journalagent.com
Methods: The study was conducted through a retrospective analysis of electronic medical
records of 830 PWH followed at the Izmir Tepecik Training and Research Hospital of Health …
records of 830 PWH followed at the Izmir Tepecik Training and Research Hospital of Health …